A biotechnology ecosystem company focused on democratizing access to drug discovery technologies, Alloy Therapeutics Inc.,announced its acquisition of Spannerwerks, LLC, a Seattle-based professional services firm specializing in guiding biopharmaceuticals through product development and launch.
Under the terms of the agreement, Spannerwerks will continue to operate as a wholly owned subsidiary under its current name, with its CEO, Dara Lockert, joining the Alloy leadership team to continue leading the organization. This strategic acquisition signifies Alloy’s evolution beyond its core discovery platforms and into the drug development space, aiming to provide partners with more efficient pathways toward key value inflection points. Alloy CEO Errik Anderson noted that combining Alloy’s discovery platforms with Spannerwerks’ established preclinical and clinical development capabilities will offer greater flexibility, speed, and expert support to move programs from "idea to patients." Since its founding in 2015, Spannerwerks has built a strong reputation by assisting pharma and biotech companies with a robust, cost-effective, and operationally focused approach, specializing in support from development candidate selection through early clinical development, encompassing cross-functional areas like program management, toxicology, CMC, regulatory, quality, and clinical operations.
Spannerwerks CEO Dara Lockert expressed excitement about joining the Alloy ecosystem, which will allow the firm to amplify its efforts in helping emerging biotechs navigate the complex path to the clinic. The acquisition deepens Alloy’s commitment to supporting partners across the entire R&D lifecycle, de-risking the path to the clinic without inflating costs, and extends the company's global reach into the Pacific Northwest, a vital hub for drug development expertise. Alloy Therapeutics ultimately seeks to empower the scientific community through its collaborative ecosystem by providing access to foundational tools, technologies, and services across six modalities, reinvesting 100% of its revenue back into innovation and access.